Zelira Therapeutics Limited (ZLDAF)
USD 0.35
(0.0%)
USD 0.35
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -35.52 Million AUD | -529.05% |
| 2023 | -5.64 Million AUD | 41.66% |
| 2022 | -11.77 Million AUD | -46.55% |
| 2021 | -8.03 Million AUD | -19.39% |
| 2020 | -7.5 Million AUD | -58.73% |
| 2019 | - AUD | -49.86% |
| 2018 | - AUD | 55.28% |
| 2017 | - AUD | -621.62% |
| 2016 | - AUD | -106.79% |
| 2015 | -423.82 Thousand AUD | -43.75% |
| 2014 | -294.84 Thousand AUD | 6.94% |
| 2013 | -316.84 Thousand AUD | 48.62% |
| 2012 | -616.67 Thousand AUD | -36.57% |
| 2011 | -451.53 Thousand AUD | 32.57% |
| 2010 | -1.09 Million AUD | 56.27% |
| 2009 | -1.53 Million AUD | -213.74% |
| 2008 | -487.99 Thousand AUD | 97.55% |
| 2007 | -19.94 Million AUD | -1533.89% |
| 2006 | -1.22 Million AUD | -420.31% |
| 2005 | -234.55 Thousand AUD | -16231.77% |
| 2004 | 1454.00 AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.5 Million AUD | -41.22% |
| 2024 Q2 | -3.06 Million AUD | 0.0% |
| 2024 FY | - AUD | 17.09% |
| 2024 Q3 | -1.26 Million AUD | 15.72% |
| 2024 Q4 | -1.26 Million AUD | 0.0% |
| 2023 Q2 | -3.22 Million AUD | -39.89% |
| 2023 Q1 | -2.3 Million AUD | 70.69% |
| 2023 FY | - AUD | 41.66% |
| 2023 Q3 | -1.74 Million AUD | 45.94% |
| 2023 Q4 | -3.64 Million AUD | -109.0% |
| 2022 FY | - AUD | -46.55% |
| 2022 Q1 | -2.52 Million AUD | 42.08% |
| 2022 Q2 | -4.96 Million AUD | -96.22% |
| 2022 Q3 | -3.83 Million AUD | 22.68% |
| 2022 Q4 | -7.86 Million AUD | -104.93% |
| 2021 Q1 | -2.36 Million AUD | -9.54% |
| 2021 FY | - AUD | -19.39% |
| 2021 Q3 | -2.13 Million AUD | 55.55% |
| 2021 Q4 | -4.36 Million AUD | -104.15% |
| 2021 Q2 | -4.81 Million AUD | -103.1% |
| 2020 Q3 | -2.08 Million AUD | -674.7% |
| 2020 FY | - AUD | -58.73% |
| 2020 Q1 | 362.44 Thousand AUD | 115.61% |
| 2020 Q2 | 362.44 Thousand AUD | 0.0% |
| 2020 Q4 | -2.16 Million AUD | -3.83% |
| 2019 FY | - AUD | -49.86% |
| 2019 Q1 | -120.18 Thousand AUD | -313.43% |
| 2019 Q2 | -120.19 Thousand AUD | -0.0% |
| 2019 Q3 | -5452.00 AUD | 95.46% |
| 2019 Q4 | -2.32 Million AUD | -42478.5% |
| 2018 Q4 | -29.07 Thousand AUD | 0.0% |
| 2018 Q3 | -29.07 Thousand AUD | -108.38% |
| 2018 Q2 | 346.77 Thousand AUD | 0.0% |
| 2018 Q1 | 346.77 Thousand AUD | 3556.01% |
| 2018 FY | - AUD | 55.28% |
| 2017 Q1 | -1.84 Million AUD | 0.0% |
| 2017 FY | - AUD | -621.62% |
| 2017 Q4 | -10.03 Thousand AUD | 0.0% |
| 2017 Q3 | -10.03 Thousand AUD | 99.46% |
| 2017 Q2 | -1.84 Million AUD | -0.0% |
| 2016 FY | - AUD | -106.79% |
| 2015 FY | - AUD | -43.75% |
| 2014 FY | - AUD | 6.94% |
| 2013 FY | - AUD | 48.62% |
| 2012 FY | - AUD | -36.57% |
| 2011 FY | - AUD | 32.57% |
| 2010 FY | - AUD | 56.27% |
| 2009 FY | - AUD | -213.74% |
| 2008 FY | - AUD | 97.55% |
| 2007 FY | - AUD | -1533.89% |
| 2006 FY | - AUD | -420.31% |
| 2005 FY | - AUD | -16231.77% |
| 2004 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 49.995% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -499.123% |
| SQZ Biotechnologies Company | -64.14 Million USD | 44.62% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -104.499% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 137.773% |
| Mesoblast Limited | -62.38 Million USD | 43.065% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2212.521% |
| Genus plc | 73.7 Million USD | 148.197% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -437.266% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -901.451% |
| Marizyme, Inc. | -34.28 Million USD | -3.617% |
| ContraFect Corporation | -64.99 Million USD | 45.351% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -304.941% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -684.797% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -2433.974% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -1243.246% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -1428.58% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -6756.814% |
| Accustem Sciences Inc. | -3.74 Million USD | -848.144% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 26.345% |
| EV Biologics, Inc. | -1.26 Million USD | -2703.295% |
| Q BioMed Inc. | -617.62 Thousand USD | -5651.269% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1094.441% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -5516.874% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -1454.897% |
| Biomind Labs Inc. | -1.03 Million USD | -3333.52% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 459.638% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -396.021% |
| Skye Bioscience, Inc. | -13.54 Million USD | -162.198% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -2288.138% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -141985.796% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -814.483% |
| IMV Inc. | -35.52 Million USD | 0.005% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -123.831% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -1319.744% |
| GB Sciences, Inc. | -1.41 Million USD | -2401.713% |
| Alpha Cognition Inc. | -9.7 Million USD | -265.989% |
| HST Global, Inc. | -5303.00 USD | -669736.866% |
| CSL Limited | 4.78 Billion USD | 100.742% |
| Halberd Corporation | -74.27 Thousand USD | -47721.658% |
| Enzolytics Inc. | -2.12 Million USD | -1573.938% |
| Resverlogix Corp. | -11.74 Million USD | -202.516% |
| Affymax, Inc. | -14.29 Million USD | -148.489% |
| SYBLEU INC | -141.57 Thousand USD | -24990.908% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1059.689% |
| argenx SE | -216.02 Million USD | 83.557% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 35.811% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 3018.771% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -2269.825% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 9476.273% |
| AVAX Technologies, Inc. | -6.11 Million USD | -481.114% |
| Zenith Capital Corp. | -8.6 Million USD | -312.752% |
| Genscript Biotech Corporation | -248.71 Million USD | 85.718% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -203800.172% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -1351.952% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -20079.848% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 10.383% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -1128.127% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -3294.919% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 528378.54% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -1929.798% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -1749.198% |
| BioStem Technologies, Inc. | -7.55 Million USD | -370.256% |
| ONE Bio Corp. | 13.61 Million USD | 360.937% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -19515.573% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -1626.857% |
| Agentix Corp. | -1.37 Million USD | -2489.487% |
| LadRx Corporation | 412.28 Thousand USD | 8715.793% |
| Cell Source, Inc. | -4.27 Million USD | -731.392% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -9573.044% |
| Regen BioPharma, Inc. | 1.46 Million USD | 2523.091% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -3691.183% |
| NovAccess Global Inc. | -1.03 Million USD | -3332.697% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 501.2% |
| Itoco Inc. | -1.86 Million USD | -1800.564% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -9257.107% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -3082.926% |
| Kadimastem Ltd | -2.62 Million USD | -1253.517% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -14753.209% |
| CytoDyn Inc. | -18.02 Million USD | -97.024% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -44847.36% |
| Mobile Lads Corp. | -2.24 Million USD | -1484.959% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -290368.959% |
| Qrons Inc. | -40.08 Thousand USD | -88524.159% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -7213.786% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 6834.779% |
| Rebus Holdings, Inc. | -951 Thousand USD | -3635.168% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -3244.738% |
| International Stem Cell Corporation | 202 Thousand USD | 17684.876% |
| Bioxytran, Inc. | -3.82 Million USD | -829.845% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -67379.956% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -1342.828% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 0.969% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -78836.553% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -1197.35% |
| Neutra Corp. | -181.24 Thousand USD | -19498.365% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -76.206% |
| PureTech Health plc | -11.62 Million USD | -205.508% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -76.218% |
| IXICO plc | -707 Thousand USD | -4924.25% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -362.218% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 26.527% |
| CSL Limited | 4.73 Billion USD | 100.751% |
| Cellectis S.A. | -92.63 Million USD | 61.655% |